AI assistant
Jasper Therapeutics, Inc. — Director's Dealing 2024
Jun 13, 2024
34406_dirs_2024-06-12_a3196f6d-8cf4-4fa5-8b37-1d7c7ed481b6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jasper Therapeutics, Inc. (JSPR)
CIK: 0001788028
Period of Report: 2024-06-12
Reporting Person: Mahal Jeetinder Singh (Chief Operating Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-12 | Voting Common Stock | M | 900 | $7.10 | Acquired | 25909 | Direct |
| 2024-06-12 | Voting Common Stock | S | 900 | $24.155 | Disposed | 25009 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-06-12 | Stock Option (right to buy) | $7.10 | M | 900 | Acquired | 2030-05-31 | Voting Common Stock (900) | Direct |
Footnotes
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2023.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.975 to $24.555, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
F3: 25% of the original number of shares subject to the option vested on December 12, 2020, and 1/48th of the original number of shares subject to the option vested monthly thereafter.